Therapeutic plasma exchange (TPE) is a therapeutic strategy for severe pathologies of diverse clinical specialties including neurological, rheumatological, renal and hepatic origins, potentially life-threatening, but remarkably not mandatory for critical care. Several guidelines, such as the Japanese and American Society for Clinical Apheresis (ASFA), set the recommendations for its evidence-based use. Classically, in Latin America, TPE has been performed in Critical Care Units (ICU), usually without the use of clinical deterioration scores to objectivize ICU needs, increasing costs and reducing the opportunity to get ICU access for real critical care patients.It is pertinent for emerging economies countries to develop strategies to diminish barriers to access to strategies as TPE.